A case of pembrolizumab-induced toxic epidermal necrolysis with a delayed developmental timeline

Immunotherapy has emerged in recent years as a crucial treatment strategy for a range of nonresectable cancers.1 Programmed death-1 (PD-1) inhibitors enhance the immune system’s capacity to recognize and fight cancer cells.1 As a side effect of this more active immune system, patients often experience immune-related adverse effects.1 Most commonly, PD-1 inhibitors induce cutaneous side effects, with overall rates of adverse cutaneous events as high as 42% in prior studies.2 Most of these events are mild, but severe reactions, including Steven–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), can occur.